US 12,257,326 B2
TCO conjugates and methods for delivery of therapeutic agents
Jose Manuel Mejia Oneto, Oakland, CA (US); and Maksim Royzen, Albany, NY (US)
Assigned to THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, Albany, NY (US); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US); and THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, Albany, NY (US)
Filed on Sep. 11, 2020, as Appl. No. 17/018,314.
Application 17/018,314 is a continuation of application No. 16/156,418, filed on Oct. 10, 2018, granted, now 10,806,807.
Application 16/156,418 is a continuation of application No. 15/382,402, filed on Dec. 16, 2016, granted, now 10,130,723, issued on Nov. 20, 2018.
Application 15/382,402 is a continuation of application No. 15/265,158, filed on Sep. 14, 2016, granted, now 10,342,882, issued on Jul. 9, 2019.
Application 15/265,158 is a continuation of application No. PCT/US2015/020718, filed on Mar. 16, 2015.
Claims priority of provisional application 62/083,022, filed on Nov. 21, 2014.
Claims priority of provisional application 62/013,994, filed on Jun. 18, 2014.
Claims priority of provisional application 61/953,294, filed on Mar. 14, 2014.
Prior Publication US 2021/0060188 A1, Mar. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/06 (2006.01); A61K 31/43 (2006.01); A61K 31/7076 (2006.01); A61K 38/12 (2006.01); A61K 38/14 (2006.01); A61K 47/54 (2017.01); A61K 47/61 (2017.01); A61K 47/66 (2017.01); A61K 47/69 (2017.01); A61K 49/00 (2006.01); A61K 51/04 (2006.01); A61K 51/12 (2006.01); C07D 257/08 (2006.01); C07D 311/82 (2006.01); C07D 499/74 (2006.01); C07H 7/02 (2006.01); C07H 15/24 (2006.01); C07H 19/167 (2006.01); C07H 19/213 (2006.01)
CPC A61K 51/065 (2013.01) [A61K 31/43 (2013.01); A61K 31/7076 (2013.01); A61K 38/12 (2013.01); A61K 38/14 (2013.01); A61K 47/54 (2017.08); A61K 47/542 (2017.08); A61K 47/545 (2017.08); A61K 47/61 (2017.08); A61K 47/665 (2017.08); A61K 47/6903 (2017.08); A61K 49/0041 (2013.01); A61K 49/0043 (2013.01); A61K 49/0052 (2013.01); A61K 49/0054 (2013.01); A61K 49/0073 (2013.01); A61K 51/0482 (2013.01); A61K 51/0495 (2013.01); A61K 51/1213 (2013.01); C07D 257/08 (2013.01); C07D 311/82 (2013.01); C07D 499/74 (2013.01); C07H 7/02 (2013.01); C07H 15/24 (2013.01); C07H 19/167 (2013.01); C07H 19/213 (2013.01)] 20 Claims
 
1. A solid support composition comprising:
a biocompatible solid support;
at least one binding agent; and
a linker comprising from about 1 to about 10 linking atoms, covalently linking each binding agent to the biocompatible solid support,
wherein the binding agent and the linker together have the structure selected from the group consisting of:

OG Complex Work Unit Chemistry